ABSTRACT N,N-dimethyl-n-octadecylamine borane 1 at 8 mg/kg/day, tetrakis-u-(trimethylamine boranecarboxylato)-bis(trimethyl-carboxyborane)-dicopper(I I) 2_ at 2.5 mg/kg/day and trimethylamine-carboxyborane 3 at 8 mg/kg/day were evaluated for their effects on bile lipids, bile acids, small intestinal absorption of cholesterol and cholic acid and liver and small intestinal enzyme activities involved in lipid metabolism. The agent administered orally elevated rat bile excretion of lipids, e.g. cholesterol and phospholipids, and compounds 2 and 3 increased the bile flow rate. These agents altered the composition of the bile acids, but there was no significant increase in lithocholic acid which is most lithogenic agent in rats. The three agents did decrease cholesterol absorption from isolated in s#u intestinal duodenum loops in the presence of drug. Hepatic and small intestinal mucosa enzyme activities, e.g. ATP-dependent citrate lyase, acyl CoA cholesterol acyl transferase, cholesterol-7-c-hydroxylase, sn.glycerol-3-phosphate acyl transferase, phosphatidylate phosphohydrolase, and lipoprotein lipase, were reduced. However, the boron derivatives 1 and 3 decreased hepatic HMG-CoA reductase activity, the regulatory enzyme for cholesterol synthesis, but the compounds had no effects on small intestinal mucosa HMG-CoA reductase activity. There was no evidence of hepatic cell damage afforded by the drugs based on clinical chemistry values which would induce alterations in bile acid concentrations after treatment of the rat.
INTRODUCTION
Previously we have demonstrated that certain boron derivatives are potent hypolipidemic agents in rats at dose ranges of 2.5-20 mg/kg/day. [1] [2] [3] These agents demonstrated significant reductions in both rat serum cholesterol and triglyceride levels after 14 days administration. Perhaps more importantly, selected derivatives were able to lower cholesterol content of VLDL and LDL, and elevate HDL cholesterol levels in rats [4] . Preliminary acute toxicity studies have demonstrated that these agents have no deleterious side effects based on organ weights, clinical chemistry levels, hematopoietic parameters and histological examination of major organs of mice and rats [5] . Initial studies on the bile indicated that lipid content was modulated by drug therapy with increases in cholesterol and phospholipid content after 14 days [1] [2] [3] . Clinical treatment with hypolipidemic agents have produced cholelithiasis or cholestasis. Therefore, a detailed analysis of rat bile lipid and bile acids after treatment with these agents was addressed along with studies on lipid regulatory enzyme activities and lipid distribution to clarify the characteristics of these agents on bile excretion and intestinal metabolism.
MATERIALS AND METHODS N,N-Dimethyl-n-octadecylamine borane I was synthesized according to the literature preparation of Hall et al. [1] .
Tetrakis-u-(trimethylamine-boranecarboxylato)-bis(trimethylaminecarboxyborane)-dicopper(ll) 2 was prepared by the method of Hall et al. [2] . Trimethylaminecarboxyborane 3 was synthesized as outlined by Hall et al. [3] . Drugs were prepared in 1% carboxymethylcellulose and homogenized.
Control animals were maintained on 1% carboxymethylcellulose as a vehicle treated group. All [16] , acetyI-CoA synthetase [17] , HMG-CoA reductase [18, 19] , acyI-CoA-cholesterol-acyl transferase [20] , neutralcholesterol-ester-hydrolases [21] , cholesterol-7-cx-hydroxylase [22] , acetyI-CoA carboxylase [23] , sn-glycerol-3-phosphate acyl transferase [24] , phosphatidylate phosphohydrolase [25] and lipoprotein lipase [26] . Clinical Chemistry Levels: Blood was collected from the control and treated rats from the abdominal vein after lightly anesthetizing the animal with ether. Sigma chemistry kits were used to analyze SGPT (no. 505), glucose (no. 510) alkaline phosphatase (AP no. 104) LDH (no. 500), and direct bilirubin (no 605). Bile salts and uric acid were determined by the method of Tietz [27] . The animals were killed by carbon dioxide asphyxiation. After all vital signs had ceased, a midline incision was made from the lower jaw to the inguinal area. Thymus, spleen, liver and kidney were excised and weighed. Representative tissue samples were fixed in 10% buffered formalin, trimmed and sectioned at 6u in thickness and stained with hematoxylin and eosin. Data displayed in Tables I-VI 
DISCUSSION
The hypolipidemic agents nafedopin [28] and clofibrate [29] increased the bile flow of rats.
Similarly the trimethylamine carboxyborane 3 and dicopper complex 2 increased bile flow in treated rats after 14 days. The addition of boron derivatives into the lumen of the intestine of rats was effective in decreasing the absorption of cholesterol from intestinal loops, suggesting that the drug is effective in blocking the absorption of cholesterol consumed orally in the diet as well as enterohepatic recirculating cholesterol and possibily cholic acids from bile excretion. Previous studies with boron derivatives have shown that orally administered 3H-cholesterol to intact treated rats is reduced in the blood after 24 hrs compared to that of control animals [1] [2] [3] [33] . The lack of significant increases in any of these three bile acids which would suggest that these boron derivates are not lithogenic at 2.5-8 mg/kg/day for 14 days. No unidentified bile acids were noted in the treated rats in this study. Gall stone formation has been linked with high levels of hepatic HMG-CoA reductase activity and low level levels of cholesterol-7-a-hydroxylase activity [29] . In rats it has been observed that the rate of hepatic cholesterol synthesis, the levels of cholesterol esters regulated by acyI-CoA-acyl-transferase activity and the amount of cholesterol absorbed from the intestine play no role in cholesterol secretion into the bile [29] . 
